FOLH1 and neoplasm: Furthermore, a 4.2-fold upregulation of PSMA in 20 tumor-bearing mice (LNCaP xenograft) followed 23 days with 10 mg/kg enzalutamide or 50 mg/kg bicalutamide QD, assessed by flow-cytometric quantification of tumor biopsies at 4 h, 48 h and 96 h post-RLT [69].